Manuel Viamonte, MD
Colon & Rectal Surgery · Miami Beach, FLNPI 1033172978
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $12,188 of the $15,726 with a category attached, or 77.5%. 26 manufacturers reported payments, led by Medical Device Business Services, Inc. at 49.4% of the total. Reporting peaked in 2023 at $5,303 and has fallen 57.1% since, to $2,274 in 2025.
Across 94 payments — averaging $167.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medical Device Business Services, Inc.$8K
- Johnson & Johnson$3K
- Medtronic$3K
- Ovesco Endoscopy USA, Inc.$601
- Myriad Genetic Laboratories, Inc.$347
- Northgate Technologies, Inc.$300
- plus $704 from 20 others
Across 51 payments — averaging $2692.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$133K
- AbbVie$5K
What the payments were for
- Consulting fees$12,18878%
- Travel & lodging$6014%
- Food & beverage$2,93719%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medical Device Business Services, Inc. | 10 | $7,772 |
| Johnson & Johnson(3 entities) | 17 | $3,326 |
| Medtronic(2 entities) | 17 | $2,675 |
| Ovesco Endoscopy USA, Inc. | 1 | $601 |
| Myriad Genetic Laboratories, Inc. | 17 | $347 |
| Northgate Technologies, Inc. | 1 | $300 |
| AbbVie | 4 | $90 |
| Merck | 4 | $73 |
| Mallinckrodt Hospital Products Inc. | 2 | $66 |
| Innovation Technologies Inc | 1 | $65 |
| Livanova USA, Inc. | 3 | $65 |
| Integra Lifesciences Corporation | 1 | $52 |
| Boston Scientific | 1 | $36 |
| Braintree Laboratories, Inc. | 2 | $30 |
| AstraZeneca | 2 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $28 |
| Celltrion USA Inc. | 1 | $23 |
| Eisai Inc. | 1 | $22 |
| Abbott | 1 | $20 |
| Bayer | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| GSK | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Redhill Biopharma Inc. | 1 | $16 |
| Angiodynamics, Inc. | 1 | $14 |
| THD America, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Echelon Flex$4,500
- DERMABOND Portfolio$2,925
- ECHELON FLEX Stapler$2,925
- Enseal$2,063
- Enseal X1$2,063
- ETHICON$2,063
- VISTASEAL$325
- GI Genius$175
- INTERSTIM$140
- VISTASEAL Fibrin Sealant (Human)$120
- Mega Power$120
- Mega Soft$120
- Mega Vac$120
- Ultra Vac$120
- STRATAFIX$104
How this compares
$15,726 in reported general payments places this provider in the 70th percentile of 157 colon & rectal surgery providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 75 | $42,528 |
| SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag | 19 | $2,385 |
| Desoximetasone | 71 | $1,329 |
| CholestyramineCholestyramine (With Sugar) | 12 | $1,051 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 60 | $704 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 16 | $257 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 12 | $236 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 39 | $231 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 15 | $141 |
| Neomycin Sulfate | 20 | $123 |
| Metronidazole | 18 | $88 |
| Gabapentin | 18 | $8 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $90 | $42,52875 claims |
| Braintree Laboratories, Inc.Suflave | $30 | $2,38519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 157 colon & rectal surgery providers in Florida.
Other colon & rectal surgery in Miami Beach
- Mark SolimanAltamonte Springs$872K
- Eduardo Parra DavilaWest Palm Beach$577K
- Matthew AlbertAltamonte Springs$514K
- Avraham BelizonBoca Raton$482K
- Rahila EssaniCelebration$379K
- Henry LujanMiami$378K
- Steven WexnerWeston$333K
- Allen ChudzinskiTampa$252K
- Ron LandmannJacksonville$224K
- Luis HernandezMiami$220K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.